DIABETES DRUG SEMAGLUTIDE SHOWS PROMISE IN REDUCING DEMENTIA RISK
Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).
Dementia, a condition that slowly makes it harder for people to remember things and think clearly, occurs when brain cells are damaged and their connections stop working properly. This damage, which worsens over time, can be caused by various modifiable factors, including obesity, T2D, cardiovascular diseases, traumatic brain injury and stroke.
According to the National Institutes of Health, more than 6 million people in the United States are diagnosed with dementia, and it causes more than 100,000 deaths each year. Encouragingly, research indicates that 45% of dementia cases could be prevented by addressing modifiable risk factors.
2025-06-24T12:20:08Z